Drug Information

Drug General Information
Drug ID
D0W5FA
Former ID
DIB000021
Drug Name
Liposomal lurtotecan
Synonyms
OSI-211
Drug Type
Small molecular drug
Indication Lung cancer [ICD9: 162; ICD10:C33-C34] Discontinued in Phase 1 [546810]
Company
OSI Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C28H30N4O6
Canonical SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC6=C(C=C5N=C4C3=C2)OC<br />CO6)CN7CCN(CC7)C)O
InChI
1S/C28H30N4O6/c1-3-28(35)20-11-22-25-18(14-32(22)26(33)19(20)15-38-27(28)34)17(13-31-6-4-30(2)5-7-31)16-10-23-24(12-21(16)29-25)37-9-8-36-23/h10-12,35H,3-9,13-15H2,1-2H3/t28-/m0/s1
InChIKey
RVFGKBWWUQOIOU-NDEPHWFRSA-N
PubChem Compound ID
60956
PubChem Substance ID
8187138, 12014791, 14860589, 14909576, 43118270, 50064479, 50513944, 57314197, 81044630, 103267653, 103943995, 104322041, 129186682, 135105103, 137100870, 142408262, 162222447, 179150007, 198982376, 226409017
Target and Pathway
Target(s) DNA topoisomerase I Target Info Inhibitor [527009]
WikiPathways Integrated Pancreatic Cancer Pathway
References
Ref 546810Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010410)
Ref 527009Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 1;100(7):1449-58.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.